Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Sotorasib improves PFS over docetaxel in KRASG12C-mutated advanced NSCLC
The first-in-class KRASG12C inhibitor sotorasib significantly improved progression-free survival (PFS) in patients with previously treated non-small cell lung cancer (NSCLC) with KRASG12C mutations, according to results of the phase III CodeBreaK 200 trial presented at ESMO 2022.
Sotorasib improves PFS over docetaxel in KRASG12C-mutated advanced NSCLC
15 Dec 2022
Coexisting diabetes ups risk of secondary malignancy, death in cancer patients
In cancer patients, the presence of diabetes appears to aggravate the likelihood of developing a secondary malignancy or death, reports a recent Japan study.
Coexisting diabetes ups risk of secondary malignancy, death in cancer patients
15 Dec 2022
Prophylactic G-CSF averts febrile neutropaenia in docetaxel-treated breast cancer patients
Prophylactic granulocyte-colony stimulating factor (G-CSF) results in a significant decrease both in the rate of febrile neutropaenia (FN) and duration of hospitalization for FN in breast cancer patients treated with docetaxel-based chemotherapy regimens (DBRs), according to a recent study.
Prophylactic G-CSF averts febrile neutropaenia in docetaxel-treated breast cancer patients
14 Dec 2022
Palbociclib–bazedoxifene combo for HR+/HER2− breast cancer succeeds in early trial
Treatment with the combination of palbociclib plus bazedoxifene demonstrates clinical efficacy while having an acceptable safety profile in treatment-experienced patients with hormone receptor–positive/HER2-negative (HR+/HER2−) advanced breast cancer, according to the results of a phase Ib/II study.
Palbociclib–bazedoxifene combo for HR+/HER2− breast cancer succeeds in early trial
14 Dec 2022
Acalabrutinib-based chemo-free triplet shows high rates of MRD-negative CR in 1L MCL study
First-line (1L) acalabrutinib in combination with lenalidomide and rituximab (ALR) has demonstrated high rates of minimal residual disease (MRD)–negative complete remission (CR) in patients with mantle cell lymphoma (MCL), including patients with TP53 mutations, in a single-arm phase II trial reported at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition.
Acalabrutinib-based chemo-free triplet shows high rates of MRD-negative CR in 1L MCL study
14 Dec 2022
Prostate cancer genomic study shows disparity between Chinese and Caucasians with castration-sensitive disease
A large genomic study involving 1,016 Chinese patients with prostate cancer has revealed important differences in castration-sensitive disease between Chinese and Caucasian patients, but the mutation profile of metastatic castration-resistant prostate cancer (mCRPC) is similar between the populations.
Prostate cancer genomic study shows disparity between Chinese and Caucasians with castration-sensitive disease
13 Dec 2022
Asians with MET exon 14 skipping NSCLC achieve durable response with tepotinib
The MET inhibitor tepotinib demonstrates clinically meaningful antitumour activity, with durable efficacy and manageable safety profile in Asian nonsmall cell lung cancer (NSCLC) patients with MET mutations associated with exon 14 skipping, as shown in the subset analysis of the single-arm, phase II VISION study.
